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ABSTRACT 
 
Sortase A is a membrane enzyme responsible for the anchoring of surface-exposed proteins to the 
cell wall envelope of Gram-positive bacteria. As a well-studied member of the sortase subfamily 
catalysing the cell wall anchoring of important virulence factors to the surface of staphylococci, 
enterococci and streptococci, sortase A plays a critical role in Gram-positive bacterial pathogenesis. 
It is thus considered a promising target for the development of new anti-infective drugs that aim to 
interfere with important Gram-positive virulence mechanisms, such as adhesion to host tissues, 
evasion of host defences, and biofilm formation. The additional properties of sortase A as an 
enzyme that is not required for Gram-positive bacterial growth or viability and is conveniently 
located on the cell membrane making it more accessible to inhibitor targeting, constitute additional 
reasons reinforcing the view that sortase A is an ideal target for anti-virulence drug development. 
Many inhibitors of sortase A have been identified to date using high-throughput or in silico 
screening of compound libraries (synthetic or natural), and while many have proved useful tools for 
probing the action model of the enzyme, several are also promising candidates for the development 
into potent inhibitors. This review is focused on the most promising sortase A inhibitor compounds 
that are currently in development as leads towards a new class of anti-infective drugs that are 
urgently needed to help combat the alarming increase in antimicrobial resistance.  
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1. Introduction 
 
 
Gram-positive bacteria are a significant cause of nosocomial and community-acquired infections 
associated with diseases of high morbidity and mortality. Moreover, antibiotic resistance of 
important Gram-positive pathogens, such as Staphylococcus aureus, Streptococcus pneumoniae and 
Enterococcus faecalis is one of the major worldwide health problems [1].  
Recent increasing antimicrobial resistance combined with a prominent lack of pharmaceutical 
investment into the development of new antibiotics, has stimulated research into alternative 
strategies to conventional antibiotics for counteracting bacterial pathogens [2]. Over the last decade, 
many studies have focused on agents that target the virulence of important pathogens without 
killing or inhibiting their growth therefore imposing limited selective pressure to promote the 
development and spread of resistance mechanisms [3].  
The role of sortase enzymes in the virulence of many Gram-positive pathogens, including 
staphylococci, streptococci, enterococci and Listeria monocytogenes, is well established, making 
sortases good targets for the design of new agents that can interfere with pathogenesis [4]. A 
phylogenetic analyses of 61 sortase genes encoded in 22 Gram-positive bacterial genomes has 
grouped sortases into four different classes (A to D) [5]. Sortase A (SrtA) is present in almost all 
strains belonging to low GC% Gram-positive species and plays an important role in different stages 
of the pathogenic process in many Gram-positive bacteria[6].  
The scope of this review is to describe state of the art approaches in screening for and identifying 
novel compounds (chemically synthesized or obtained from natural sources) that act as potent 
Sortase A inhibitors, as well as the research efforts into their development as anti-virulence drugs 
for the alternative or complementary treatment of infectious diseases in the near future. 
 
 
2. Sortase A is an ideal antivirulence target  
Sortase A (SrtA) is a membrane-bound cysteine transpeptidase that is responsible for catalysing the 
covalent anchoring of surface proteins to the Gram-positive bacterial cell wall. In S. aureus, these 
surface proteins are known as microbial surface components recognizing adhesive matrix molecules 
(MSCRAMMs) and play significant roles in bacterial adhesion and invasion of host tissues, biofilm 
formation, and immune evasion by inhibition of opsonization and phagocytosis. Thus, many 
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MSRAMMs are indispensable virulence factors that can determine the severity of S. aureus 
infections and SrtA is tightly linked to their correct biogenesis on the cell surface [6]. 
Proteins destined for cell wall anchoring are directed for secretion by their N-terminal signal 
sequence and the Sec pathway [7]. These proteins also possess a signature known as the cell wall 
sorting signal [9][4], which consists of an LPXTG motif at the carboxyl terminus, a hydrophobic 
region and a tail of charged amino acids [8]. During secretion the LPXTG motif is recognized by 
the membrane-bound SrtA and cleaved between the Thr and Gly residues, followed by the 
formation of a thioester acyl-enzyme intermediate. Transpeptidation is then mediated by SrtA 
through amide linkage of the C-terminal Thr of the protein to pentaglycine cross bridges in S. 
aureus. It has been suggested that SrtA uses the cell wall precursor lipid II and that the proteins 
linked to lipid II are subsequently incorporated into the peptidoglycan [10]. In S. aureus, LPXTG 
proteins are anchored to the cell wall cross bridges but not all Gram-positive bacteria have the same 
pentaglycine cross bridge and other acceptor sites, such as the meso-diaminopimelic acid of L. 
monocytogenes, have also been encountered [11]. There are around 20 staphylococcal proteins that 
carry a C-terminal LPXTG motif, including protein A (Spa), two fibronectin binding proteins 
(FnbpA and FnbpB), two clumping factors (ClfA and ClfB), a collagen-binding protein (Cna) and 
three serine-aspartate repeat proteins (SdrC, SdrD, and SdrE) [12]. For some of these proteins, a 
direct role in biofilm formation has been reported [13] (Table 1).  
In a study examining 72 microbial genomes, it was observed that approximately 20% of sortase 
homologues are very similar to the S. aureus SrtA and play a housekeeping role anchoring a large 
number of LPXTG proteins to the cell surface. In contrast, other members of the sortase family are 
more specialized and perform functions other than cell wall anchoring, such as iron-uptake, pili 
formation etc. [14]. The S. aureus SrtA active site contains two amino acid residues (cysteine 184 
and histidine 120) that are essential and highly conserved among sortase homologues found in other 
Gram-positive pathogens, including L. monocytogenes [16], S. pneumoniae [17] and S. pyogenes 
[18]. The structure and function of S. aureus SrtA has been the focus of intense study [15] and 
while a comprehensive account of this work is beyond the scope of this review, it is important to 
note that the availability of such detailed biochemical and structural information for SrtA is an 
important prerequisite when considering bacterial targets that are ideal for pharmacological 
inhibition.  
When considering bacterial targets for antivirulence approaches, it is also ideal that the protein 
target is strongly linked to bacterial pathogenesis; this link has been demonstrated for SrtA by 
several studies. In a landmark study by Mazmanian et. al. in 2000, gene knockout mutants of srtA in 
S. aureus were shown to result in defective surface expression of various LPXTG motif proteins 
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and a defect in establishing renal abscesses and acute infection in mice [4]. The reduced ability of a 
S. aureus srtA mutant to infect the host was also confirmed in several animal models of infection, 
including a rat endocarditis model, by a subsequent study [20]. Inhibition of SrtA in S. aureus by 
potent compounds or by srtA gene deletion resulted in virulence attenuation through loss of binding 
activity to IgG, fibronectin, and fibrinogen [19][4]. In addition, SrtA contributes to S. aureus 
survival inside macrophages following phagocytosis, as srtA mutants were found to be more 
susceptible to killing by macrophages [24]. It was recently demonstrated that overexpression of 
SrtA resulted in increased levels of biofilm formation in some staphylococcal strains [26]. In 
agreement with these findings, loss of SrtA in five S. aureus clinical isolates significantly reduced 
their ability to form biofilms -an important virulence mechanism of clinical S. aureus strains- and 
strong biofilm growth was restored upon SrtA complementation [25]. Similarly, loss of sortase 
activity in other Gram-positive pathogens, including L. monocytogenes[21], S. pneumoniae [22], 
and S. suis [23], results in failure to display LPTXG surface proteins and a significant attenuation in 
animal infection models. Considering that bacterial adhesion is the crucial first step of Gram-
positive pathogenesis and biofilm formation and that adhesion is promoted by several surface 
proteins at the cell wall, SrtA constitutes an ideal target for the development of new anti-virulence 
agents that will block a common enzyme responsible for linking many of these proteins to the cell 
wall rather than targeting a single surface protein involved in virulence [27].  
Additional features of SrtA that reinforce its suitability as an ideal antivirulence target, include the 
fact that (i) the enzyme is not indispensable for microbial growth and viability, therefore, SrtA 
inhibitors would likely impose less selection pressure for the development and spread of resistance 
mechanisms; (ii) as membrane enzymes, sortases would be targeted more easily by inhibitor 
compounds compared to intracellular bacterial targets; and (iii) there are no eukaryotic sortase 
homologues, therefore selective toxicity is feasible [28]. In summary and for these reasons, SrtA is 
considered an ideal target for the design of novel anti-infective drugs that will interfere with 
bacterial virulence (anti-virulence), adhesion (anti-adhesion) and biofilm formation (anti-biofilm) 
but not bacterial viability (antibiotic).  
 
 
3. Discovery of SrtA inhibitors  
 
The first important step in the synthesis of new derivatives of pharmacological interest is to identify 
a hit compound; this process can nowdays be facilitated by several different techniques. For SrtA in 
particular, High-Throughput Screening (HTS) of synthetic or natural compound libraries as well as 
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virtual screening approaches have successfully used and have identified several inhibitor hits to 
date, most of which have been used to model the action of the enzyme, while  others have provided 
promising hit compounds for the development of novel anti-virulence agents. Some of these are 
described below. 
 
3.1 High-Throughput Screening (HTS) 
 
The great advantage of HTS is that it allows the identification of active molecules among thousands 
of screened compounds. For this reason it has been widely used in the search of new and potent 
SrtA inhibitors [29]. A powerful biochemical assay that was combined with fluorescence resonance 
energy transfer (FRET) has allowed the in vivo monitoring of SrtA enzymatic activity in S. aureus. 
Specifically, SrtA activity is measured by monitoring the cleavage of a fluorescence resonance 
energy transfer substrate, such as peptide Abz-LPETG-Dnp, between the Thr and Gly residues [30] 
[31] [32]. Using HTS of a library of 1,000 compounds and recombinant SrtA, Oh et al. discovered 
diarylacrylonitriles as a novel class of small molecule SrtA inhibitors [33]. Subsequently, Suree et 
al. performed a HTS using a larger compound library (30,000) and identified several pyridazone 
and pyrazolethione derivatives that inhibited SrtA, with submicromolar IC50 values [34]. The 
authors evaluated the S. aureus SrtA inhibition percentage using two criteria: 1) the initial velocity 
and 2) the end point of product formation. Using a similar approach, Maresso et al. screened 
135,625 small molecules as inhibitors of S. aureus SrtA and identified a total of 407 active 
compounds belonging to five different classes on the basis of a common structural core: 1. aryl (β-
amino)ethyl ketones, 2. N-aryl maleamides and aryl fumaramides, 3. N,4-diaryl-2-aminothiazoles, 
4. 3-heteroatom-substituted (N-alkyl/aryl)pyrrolidine-2,5-diones and 5. variously substituted 
maleimide-furan Diels-Alder products. The aryl (β -amino)ethyl ketones (AAEK) were determined 
to be the most active inhibitors of sortases from staphylococci and bacilli [35].  Some of these 
promising compounds will be described in more detail in the following sections. 
 
3.2 Virtual screening 
 
As the crystal structure of S. aureus SrtA is available, another popular method for the identification 
of new active compounds is the in silico screening of commercial compound libraries. For their 
study, Chenna et al. selected the high resolution structure of recombinant S. aureus SrtA∆59 [36], 
and using flexible docking (FLEX software package) they fit approximately 150,000 small 
molecules into the enzyme active site [37]. The top scoring compounds were screened against S. 
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aureus SrtA∆59 in order to confirm the reliability of the model used and 7.4%  (8 of 108 molecules) 
of the identified leads exhibited SrtA inhibition in vitro with IC50 values ranging between 75 and 
400 µM. Recently, Chan et al. employed a different virtual screening method in which a total of 
55,789 ligands were docked into the NMR structure of holo-SrtA (PDB: 2KID) taking into account 
protein receptor flexibility. This screen identified 42.2% of lead molecules that displayed activity 
against SrtA with IC50 values ranging from 47 to 368 µM [38]. The same NMR structure of S. 
aureus SrtA was also used in a very recent study that demonstrated SrtA inhibition by tetralene and 
indene compounds previously described to have inhibitory activity against Mycobacterium 
tuberculosis [39]. LigandFit (Accelrys) was used as the docking protocol and Ligand scoring 
functions were evaluated for estimating the binding affinity of the compounds towards the active 
site of the SrtA protein. This method has allowed the identification of three compounds belonging 
to tetralene and indene series as new S. aureus SrtA inhibitors [39]. 
 
4. Synthetic small molecules 
 
Many of the promising compound hits identified by large library high-throughput or virtual screens 
have been elaborated further and developed into lead candidates for antivirulence drugs targeting 
SrtA. Following a small molecule screen for new SrtA inhibitors, Oh et al. identified methyl(2E)-
2,3-bis(4-methoxyphenyl)prop-2-enoate (Fig. 1, Compound 1) as a promising hit with an IC50 value 
of 231 µM and used it as a starting point for further elaboration [33]. Their activity data suggested 
that the introduction of a nitrile group and the correct positioning of two phenyl groups are essential 
for SrtA inhibition. Among the diarylacrylonitriles that were synthesized and tested for SrtA 
inhibitory activity (Z)-3-(2,5-dimethoxyphenyl)-2-(4-methoxyphenyl) acrylonitrile (DMMA) was 
the most active compound with an IC50 value of 9.2 µM (Fig. 1, Compound  2). Kinetics studies 
demonstrated that this compound behaved as a competitive inhibitor with a Ki of 6.81 µM and 
displayed reversible SrtA binding activity. The authors investigated the interactions between the 
diarylacrylonitrile derivative and the SrtA enzyme (PDB:1IJA) using molecular modelling. 
Although DMMA does not form an interaction with Cys 184, which is crucial for transpeptidation 
activity, the nitrile group forms a hydrogen bond with the catalytic residue Arg 197 [40], and the 
phenyl rings form strong lipophilic interactions with amino acids in the large hydrophobic binding 
pocket of the SrtA active site. A subsequent study examined the inhibitory effects of DMMA in 
vivo providing the first data of SrtA inhibitor use in animals [41]. Balb/c mice experimentally 
infected with 107 CFU of S. aureus Newman were treated with DMMA at doses of 100, 20 and 4 
mg/Kg and showed a survival rate of 75%, 100% and 97%, respectively. In addition to reduced 
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mortality, intravenously administered DMMA decreased infection of the kidneys and joints, which 
are sites associated with SrtA-mediated pathogenesis. The fact, however, that mouse survival rates 
were the lowest at the highest administered DMMA dose suggested potential toxicity of the DMMA 
compound to the host. The inhibitory activity of DMMA for SrtA has also been confirmed by 
another study, which demonstrated that DMMA, together with certain natural SrtA inhibitors (β-
sitosterol-3-O-glucopyranoside, berberine chloride and psammaplin A1), can inhibit S. aureus cell 
adhesion to fibronectin via fibronectin-binding protein [19]. Beginning with the results of this study 
concerning the role of the nitrile group in the inhibition of the enzyme, and considering the activity 
showed by some vinyl sulfones, which will be described in the paragraph 6 of this review, as 
cysteine protease inhibitors [42] [43], Kudryavtsev et al. described the synthesis of novel 5-phenyl 
proline functionalizated with these two groups. Ultimately, however,  they resulted weak inhibitors 
in the order of mM [44]. 
A different class of promising SrtA inhibitor hits that are currently being developed further are the 
aryl(β-amino)ethyl ketones (AAEK) [35]. Compounds AAEK1 and AAEK2 (Fig.1, Compound 3 
and 4) displayed IC50 values of 47 µM and 15 µM, respectively, for SrtA of S. aureus, while they 
were also tested for inhibition of the SrtA homologue from B. anthracis and showed lower IC50 
values of 4.8 µM and 5.6 µM, respectively. Kinetic analysis and mass spectrometry suggested non–
competitive inhibition by an irreversible covalent modification of the thiol group of Cys184 in the 
active site. This mechanism of action expects an activation by sortases of this class of molecules via 
β-elimination leading to the formation of an olefin reactive intermediate. Mass spectrometry and X-
ray crystallographic studies of SrtA- AAEK adducts, which differ from the AAEK by the absence 
of a dimethylamine moiety, showed a thienylpropanone covalently bound to the Cys 184. 
The most recent HTS screen for potent SrtA inhibitors identified a further three promising classes 
of small molecules: rhodanines, pyridazinones and pyrazolethiones, which inhibited SrtA in a 
reversible way with IC50 values in the sub-micromolar range [34]. Although SrtA inhibition was 
shown to be reversible by all three molecule classes tested, the rhodanines were more rapid. The 
most potent compounds from each class were rhodanine, pyridazinone and  pyrazolethione with 
IC50 values of 3.7 µM, 0.20 µM and 0.30 µM, respectively (Fig. 1, Compound 5, 6 and 7). 
Derivative 6 is one of the most potent SrtA inhibitors known to date. The SAR of these compounds 
was investigated and the exact location and nature of the substituents on the pyridazinone ring 
seemed to play an important role for compound activity. This molecule probably acts on the enzyme 
through a thiol-disulfide exchange reaction with Cys 184. Many of the molecules described by 
Suree et. al. inhibited the SrtA homologue from both S. aureus and B. anthracis without any effect 
on bacterial viability, reinforcing their potential as promising anti-virulence drug candidates. A 
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recent study also employed compounds 5, 6 and 7, together with fifty other derivatives belonging to 
the three classes, to construct a pharmacophore model for S. aureus SrtA, which constituted a 
comprehensive collection of steric and electronic characteristics essential for the ligand-enzyme 
interaction [45].  
In a 2010 study, Lee et al. synthesized a series of indole-type natural product analogues, which, in 
some cases, resulted in S. aureus SrtA inhibitory activity greater than that of the reference 
compound p-hydroxymercuricbenzoic acid (p-HMB) [46][47]. In particular, compound diihydro-β-
carboline (Fig.1, Compound 8) inhibited SrtA with an IC50 of 25 µM and had no effect on bacterial 
viability [Minimum Inhibitory Concentration (MIC) against S. aureus  > 200 µg/ml] [49]. Lastly, 
another group of small SrtA inhibitors that were recently described are the morpholinobenzoate 
derivatives [50]. The most active compound of the series (Fig.1, Compound 9) showed an IC50 of 
58 µM. SAR studies highlighted the importance of the stereochemistry of the double bond; in fact 
the replacement of the E with a Z double bond or a triple bond resulted in compound activity 
reduction in the majority of cases. Other important structural characteristics of the 
morpholinobenzoates are the presence of amide carbonyl and NH groups and the oxygen atom in 
the morpholine ring. 
 
 
5. Natural products 
 
Natural products have also been shown to be active against SrtA with several classes described to 
date (Table 2). Early studies that screened large collections of medicinal plant extracts for sortase 
inhibitory activity, identified the ethyl acetate fraction from Cocculus trilobus as a potent SrtA 
inhibitor with an IC50 of 1.52 µg/ml [51]. The first natural compound with demonstrated sortase 
inhibitory activity was described by Kim et al. in 2003 and was the glucosylsterol β-sitosterol-3-O-
glucopyranoside extracted from the bulbs of Fritillaria verticillata. This compound displayed an 
IC50 value of 18.3 µg/ml that was more potent than the positive control pHMB (IC50 = 40.6 µg/ml) 
and its inhibitory potency was dependent upon the glucopyranoside side chain moiety, as the 
compound sitosterol was found to be inactive against the enzyme [52]. The natural compound β-
sitosterol-3-O-glucopyranoside also showed antibacterial activity against Bacillus subtilis, S. aureus 
and Micrococcus leuteus with a MIC value of 50, 200 and 400 µg/ml, respectively [2].  
Another promising group of natural compounds identified by these early screens of medicinal plant 
extracts is the flavonols. Flavonol quercetin was isolated from the extract of the Rhus verniciflua 
bark by bioassay-guided separation and showed, together with eight other natural flavonols of 
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similar structure, inhibitory activity for S. aureus SrtA [53]. Morin, myricetin and quercetin acted as 
potent SrtA inhibitors with IC50 values of 37.39 µM (11.29 µg/ml), 44.03 µM (13.99 µg/ml) and 
52.70 µM  (15.91 µg/ml), respectively. All flavonols tested in this study exhibited no growth 
inhibition of S. aureus Newman strain at MIC values greater than 300 µM, while they reduced 
bacterial clumping to fibrinogen in a dose-dependent manner. The inhibitory effect of morin on 
Streptococcus mutans UA159 SrtA was also evaluated and an IC50 of 27.2 µM  (8.21 µg/ml) was 
reported. Morin did not have any effect on S. mutans viability but at a concentration of 30 µM  (9 
µg/ml) it significantly reduced biofilm formation by this strain [54].  
The activity of Curcuma longa L. (turmeric) rhizome constituents against SrtA have also been 
extensively studied [55] [56][57]. The curcuminoid curcumin was shown to inhibit S. aureus SrtA 
with an IC50 value of 13.8  ± 0.7 µg/ml, showing no growth inhibition even at MIC values greater 
than 200 µg/ml, but resulting in potent inhibition of S. aureus cell adhesion to fibronectin. In fact, 
the treatment of wild type strains with curcumin reduced bacterial adherence to fibronectin-coated 
surfaces in a dose-dependent manner (2.5-20 µg/ml) [55]. Ping Hu et al. studied the inhibition of S. 
mutans SrtA activity by curcumin in vitro [56]. S. mutans is part of the commensal microbiota and 
an important cariogenic agent and its surface proteins play a predominant role  in bacterial adhesion 
to the teeth. Curcumin inhibited S. mutans SrtA with an IC50 value of 3.6 µg/ml and S. aureus SrtA 
with an IC50 value of 13.8 µg/ml; both values are far lower than the MIC and MBC values identified 
[175 µM (61.7 µg/ml) and 350 µM (123.5 µg/ml) respectively], suggesting that S. mutans growth 
and viability are not compromised at the functional concentration of curcumin. A follow-up study 
by the same group investigated the effect of curcumin on S. mutans biofilm formation, in order to 
explore its potential as an anti-caries therapeutic agent [57]. It was reported that this polyphenolic 
natural compound significantly reduced biofilm formation by S. mutans at a concentration of 15 µM 
(5.29 µg/ml). The reduction in biofilm mass did not influence planctonic S. mutans growth [57]. 
The anti-biofilm action of curcumin was attributed to a reduction in the cell wall-anchored adhesin 
PAc that mediates attachment of S. mutans to the tooth surface [58]. The isoquinoline alkaloid 
berberine chloride extracted from the Coptis chinensis rhizome, was reported as a potent inhibitor 
of sortase (IC50 = 8.7 µg/ml) with a moderate antibacterial activity against Gram-positive bacteria ( 
MIC range of 50-400 µg/ml) [59]. Recently, Oh et al. described a series of flavonoids isolated from 
the roots of Sophora flavescens that acted as S. aureus SrtA inhibitors [60]. The most active 
compound was kurarinol with an IC50 value of 107 ± 6.6 µM (48.8 µg/ml) and weak antibacterial 
activity against S. aureus [MIC of 219 µM (99 µg/ml)]. 
 Marine invertebrates, such as sponges, are a prolific source of biologically active 
compounds with many interesting modes of action and have been widely used in the search of 
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potent SrtA inhibitors. For example, bis(indole) alkaloids, consisting of two indole moieties 
connected to each other via heterocyclic units, have been isolated from the sponge Spongosorites 
sp. and evaluated for their inhibitory activity against S. aureus SrtA [61]. Among 9 isolated 
compounds belonging to two distinct classes (topsentins and hamacanthins) deoxytopsentin showed 
the most potent SrtA inhibitory activity (IC50 = 15.67 ± 0.54 µg/ml). The 4.5-dihydrogenation of the 
imidazole ring caused a total loss of SrtA inhibition (IC50 >100 µg/ml), suggesting that the SrtA 
inhibitory activity of the topsentins is greatly affected by substitutions on the imidazole ring. 
Inhibition of SrtA by bromodeoxytopsentin (SrtA IC50=19.44± 0.02 µg/ml and MIC=100 µg/ml) 
was measured in vivo using the S. aureus cell adhesion assay to fibronectin-coated plates and the 
compound was shown to reduce the capacity of the pathogen to adhere to fibronectin-coated 
surfaces in a dose dependent manner (0-40 µg/ml). A different study evaluated the SrtA inhibitory 
potential of four aaptamines, belonging to the family of 1H-benzo[de][1,6]-naphthyridine alkaloids 
that were isolated from the Aaptos aaptos marine sponge [62]. Increased anti-SrtA activity was 
observed for isoaaptamin (IC50= 3.7± 0.2 µg/ml) and the importance of the methyl group at the N-1 
position was demonstrated for SrtA inhibitory activity by this class of natural compounds. 
Isoaaptamin was also studied for inhibition of fibronectin binding by S. aureus and, like 
bromodeoxytopsentin from Spongosorites sp., it also reduced cell adherence to fibronectin-coated 
surfaces in a dose-dependent way (0-16 µg/ml). An additional class of marine compounds 
displaying antibacterial and SrtA inhibitory activity are the pyrroloiminoquinone alkaloids found in 
the sponge Sceptrella sp.. In particular, (-)-discorhabdin Z, one of the two new alkaloids 
characterized by an unusual hemiaminal group, inhibited S. aureus SrtA with an IC50 of 2.19 µg/ml 
and without deffects on microbial viability (MIC > 100 µg/ml) [63]. Moreover, a new SrtA inhibitor 
with an IC50 of 21.34 µg/ml was found among the sesterterpenes and related pentaprenyl 
hydroquinones (halisulfates and suvanine) isolated from the sponge Coscinoderma sp. In contrast to 
other SrtA inhibitors, the halisulfate compounds described in this study were found to be active 
against Gram-positive and/or Gram-negative bacteria [64]. Other marine invertebrates, such as the 
ascidian Synoicum sp., were also found to be an interesting source of bioactive compounds, 
including furarones and beta-carboline alkaloids, which along with cytotoxicity and antimicrobial 
activity were shown to have moderate SrtA inhibitory activity [65][66].   
 
 
6. Peptides 
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Another important class of known SrtA inhibitors are the substrate-derived peptides. A first report 
in 2002, described the synthesis and kinetic evaluation of two promising members of this class of 
SrtA inhibitors [67]. Peptidyl-diazomethane and peptidyl-chloromethane analogues Cbz 
(benzyloxycarbonyl)- Leu-Pro-Ala-Thr-CHN2 and Cbz-Leu-Pro-Ala-Thr-CH2Cl were both shown 
to act as time-dependent irreversible inhibitors of recombinant sortase (SrtA∆N). The peptide 
inhibitor sequences mimic the substrate recognition motif of SrtA (-Leu-Pro-Xaa-Thr-Gly-) with 
the difference that the scissile amide bond between the threonine and glycine residues was replaced 
with a diazoketone or chloromethyl ketone group. The two groups were chosen for their capacity to 
alkylate the active-site thiol group (Cys 184).  These inhibitors are able to bind the protease 
covalently, forming a Michaelis complex inactivating SrtA∆N with a velocity two-fold greater for 
the peptidyl-chloromethane with respect to the peptidyl-diazomethane. The kinetic constant for 
peptidyl-diazomethane was Ki=0.22 µM and for peptidyl-chloromethane Ki=0.21 µM, 
demonstrating a high affinity for both inhibitors [67]. 
Based on previous studies concerning the ability of the vinyl sulfone group to covalently modify the 
active site thiol in cysteine proteases [42] [43], Connolly et al. synthesized a different irreversible 
inhibitor by replacing the scissile Thr-Gly in the substrate recognition motif of SrtA with a vinyl 
sulfone group (C=C-SO2Ph) [68]. Moreover, because of the higher electrophilicity of the chloro- 
and diazomethane groups compared to the vinyl sulfone one, the rate constant of inactivation (Ki) 
for this peptide was significantly lower. Through NMR and studies on the pH dependence of SrtA 
inhibition, the existence of a thiolate-imidazolium ion pair during the transpeptidation was excluded 
and a base catalysis mechanism of action was hypothesized. Subsequently, Jung et al., using the bis-
protected L-threonine analogue (2R,3S) 3-amino-4-mercapto-2-butanol protected with silyl groups, 
synthesized two tetrapeptide analogues of the sorting sequence for SrtA and SrtB that were able to 
bind covalently to the tiol group of Cys184 in both enzymes. The activity of this compound on the 
sortases was confirmed by a reverse- phase HPLC [69]. Lastly, Kruger et al. were able to obtain 
reversible inhibitors of SrtA by using nonhydrolyzable phosphinic peptidomimetics as analogues of 
the transition state [70]. In this case, the hydrolyszable Thr-Gly bond in the LPXTG motif is 
replaced by a phosphinic isoestere. Kinetic analysis indicated weak activity as a competitive 
inhibitor with an IC50 value of 10 mM. The results of this study are inconsistent with a mechanism 
of imitation of the transition state that were previously described in studies using other peptides 
containing non-hydrolyzable phosphinic isoesteres as inhibitors of proteases [71] [72]. 
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Several studies have confirmed the important role of SrtA in bacterial pathogenesis and its potential 
as a suitable target for pharmacological inhibition. In this review, we have provided a 
comprehensive description of the current most promising molecules from a variety of different 
classes (small synthetic organic compounds and natural products) that act as SrtA inhibitors and 
have the potential of being developed into future anti-virulence drugs based on their promising 
activity at the low micromolar range.  
Most of the reviewed studies, however, report on the identification of SrtA inhibitors by using 
enzymatic models, and do not always investigate the hit compounds further in vivo or in vitro. The 
efficacy of the most promising SrtA inhibitors needs to be comprehensively evaluated in in vivo 
models of infection, including but not limited to examination of survival rates, sepsis, abscess 
formation, septic arthritis, endocarditis, etc., prior to supporting an anti-virulence role for each 
inhibitor that is worthy of further development into a novel therapeutic agent. At the minimum, in 
vitro evaluation of hit compounds on live bacterial cells, such as inhibition of biofilm formation 
and/or bacterial adhesion, should constitute a minimum requirement for the initial assessment of 
anti-virulence activity of SrtA inhibitors following demonstration of SrtA inhibition in biochemical 
assays.  
We agree with Fitzgerald-Hughes et al.[2] that the search for anti-virulence drugs alternative to 
conventional antibiotics, despite its high importance, is at its beginning in terms of pharmaceutical 
development and that new in-depth studies are urgently needed. In addition, virulence attenuation as 
a strategy to combat bacterial infections requires a good host immune response for bacterial 
clearance, as the virulence-attenuated pathogens will need to be successfully dealt with by the 
host’s immune system. This effectively eliminates immune compromised patients from being 
successfully treated with anti-virulence therapies and this caveat needs to be further explored in the 
future, perhaps by exploring combination therapies with anti-virulence and immunestimulant 
agents. 
The future of anti-virulence therapies hold great promise and excitement as many of the SrtA 
inhibitors described to date are worthy candidates for further investigation and have a clear potential 
into being developed into drugs for alternative or complementary treatment of Gram-positive 
bacterial infections. The possibility of using novel agents that target virulence mechanisms and 
biofilm formation (anti-virulence agents) in combination with current antibiotics offers potential for 
new therapeutic strategies for the treatment of chronic bacterial infections and could significantly 
impact on overcoming the problem of antibiotic resistance, which is the WHO recognised as one of 
the most important global challenges of our time. 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 13
 
References 
 
[1]  Gould IM. Antibiotic resistance: the perfect storm. Int J Antimicrob Agents 2009;34 Suppl 
3:S2–5. 
[2]  Fitzgerald-Hughes D, Devocelle M, Humphreys H. Beyond conventional antibiotics for the 
future treatment of methicillin-resistant Staphylococcus aureus infections: two novel 
alternatives. FEMS Immunol Med Microbiol 2012;65:399–412. 
[3]  Rasko DA, Sperandio V. Anti-virulence strategies to combat bacteria-mediated disease. Nat 
Rev Drug Discov 2010;9:117–28. 
[4]  Mazmanian SK, Liu G, Jensen ER, Lenoy E, Schneewind O. Staphylococcus aureus sortase 
mutants defective in the display of surface proteins and in the pathogenesis of animal 
infections. Proc Natl Acad Sci U S A 2000;97:5510–5. 
[5]  Dramsi S, Trieu-Cuot P, Bierne H. Sorting sortases: a nomenclature proposal for the various 
sortases of Gram-positive bacteria. Res Microbiol 2005;156:289–97. 
[6]  Paterson GK, Mitchell TJ. The biology of Gram-positive sortase enzymes. Trends Microbiol 
2004;12:89–95. 
[7]  Schneewind O, Missiakas D. Sec-secretion and sortase-mediated anchoring of proteins in 
Gram-positive bacteria. Biochim Biophys Acta 2013. 
[8]  Schneewind O, Model P, Fischetti VA. Sorting of protein A to the staphylococcal cell wall. 
Cell 1992;70:267–81. 
[9]  Ton-That H, Liu G, Mazmanian SK, Faull KF, Schneewind O. Purification and 
characterization of sortase, the transpeptidase that cleaves surface proteins of Staphylococcus 
aureus at the LPXTG motif. Proc Natl Acad Sci U S A 1999;96:12424–9. 
[10]  Perry AM, Ton-That H, Mazmanian SK, Schneewind O. Anchoring of surface proteins to the 
cell wall of Staphylococcus aureus. III. Lipid II is an in vivo peptidoglycan substrate for 
sortase-catalyzed surface protein anchoring. J Biol Chem 2002;277:16241–8. 
[11]  Dhar G, Faull KF, Schneewind O. Anchor structure of cell wall surface proteins in Listeria 
monocytogenes. Biochemistry (Mosc) 2000;39:3725–33. 
[12]  Nandakumar R, Nandakumar MP, Marten MR, Ross JM. Proteome analysis of membrane and 
cell wall associated proteins from Staphylococcus aureus. J Proteome Res 2005;4:250–7. 
[13]  Tsompanidou E, Denham EL, Sibbald MJJB, Yang X-M, Seinen J, Friedrich AW, et al. The 
sortase A substrates FnbpA, FnbpB, ClfA and ClfB antagonize colony spreading of 
Staphylococcus aureus. PloS One 2012;7:e44646. 
[14]  Comfort D, Clubb RT. A comparative genome analysis identifies distinct sorting pathways in 
gram-positive bacteria. Infect Immun 2004;72:2710–22. 
[15]  Mazmanian SK, Ton-That H, Schneewind O. Sortase-catalysed anchoring of surface proteins 
to the cell wall of Staphylococcus aureus. Mol Microbiol 2001;40:1049–57. 
[16]  Garandeau C, Réglier-Poupet H, Dubail I, Beretti J-L, Berche P, Charbit A. The sortase SrtA 
of Listeria monocytogenes is involved in processing of internalin and in virulence. Infect 
Immun 2002;70:1382–90. 
[17]  Paterson GK, Mitchell TJ. The role of Streptococcus pneumoniae sortase A in colonisation 
and pathogenesis. Microbes Infect Inst Pasteur 2006;8:145–53. 
[18]  Race PR, Bentley ML, Melvin JA, Crow A, Hughes RK, Smith WD, et al. Crystal structure of 
Streptococcus pyogenes sortase A: implications for sortase mechanism. J Biol Chem 
2009;284:6924–33. 
[19]  Oh K-B, Oh M-N, Kim J-G, Shin D-S, Shin J. Inhibition of sortase-mediated Staphylococcus 
aureus adhesion to fibronectin via fibronectin-binding protein by sortase inhibitors. Appl 
Microbiol Biotechnol 2006;70:102–6. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 14
[20]  Weiss WJ, Lenoy E, Murphy T, Tardio L, Burgio P, Projan SJ, et al. Effect of srtA and srtB 
gene expression on the virulence of Staphylococcus aureus in animal models of infection. J 
Antimicrob Chemother 2004;53:480–6. 
[21]  Bierne H, Mazmanian SK, Trost M, Pucciarelli MG, Liu G, Dehoux P, et al. Inactivation of 
the srtA gene in Listeria monocytogenes inhibits anchoring of surface proteins and affects 
virulence. Mol Microbiol 2002;43:869–81. 
[22]  Kharat AS, Tomasz A. Inactivation of the srtA gene affects localization of surface proteins 
and decreases adhesion of Streptococcus pneumoniae to human pharyngeal cells in vitro. 
Infect Immun 2003;71:2758–65. 
[23]  Vanier G, Sekizaki T, Domínguez-Punaro MC, Esgleas M, Osaki M, Takamatsu D, et al. 
Disruption of srtA gene in Streptococcus suis results in decreased interactions with endothelial 
cells and extracellular matrix proteins. Vet Microbiol 2008;127:417–24. 
[24]  Kubica M, Guzik K, Koziel J, Zarebski M, Richter W, Gajkowska B, et al. A potential new 
pathway for Staphylococcus aureus dissemination: the silent survival of S. aureus 
phagocytosed by human monocyte-derived macrophages. PloS One 2008;3:e1409. 
[25]  O’Neill E, Pozzi C, Houston P, Humphreys H, Robinson DA, Loughman A, et al. A novel 
Staphylococcus aureus biofilm phenotype mediated by the fibronectin-binding proteins, 
FnBPA and FnBPB. J Bacteriol 2008;190:3835–50. 
[26]  Sibbald MJJB, Yang X-M, Tsompanidou E, Qu D, Hecker M, Becher D, et al. Partially 
overlapping substrate specificities of staphylococcal group A sortases. Proteomics 
2012;12:3049–62. 
[27]  Chen L, Wen Y. The role of bacterial biofilm in persistent infections and control strategies. 
Int J Oral Sci 2011;3:66–73. 
[28]  Suree N, Jung ME, Clubb RT. Recent advances towards new anti-infective agents that inhibit 
cell surface protein anchoring in Staphylococcus aureus and other gram-positive pathogens. 
Mini Rev Med Chem 2007;7:991–1000. 
[29]  Zhang, Chung, Oldenburg. A Simple Statistical Parameter for Use in Evaluation and 
Validation of High Throughput Screening Assays. J Biomol Screen 1999;4:67–73. 
[30]  Sekar RB, Periasamy A. Fluorescence resonance energy transfer (FRET) microscopy imaging 
of live cell protein localizations. J Cell Biol 2003;160:629–33. 
[31]  Kruger RG, Dostal P, McCafferty DG. Development of a high-performance liquid 
chromatography assay and revision of kinetic parameters for the Staphylococcus aureus 
sortase transpeptidase SrtA. Anal Biochem 2004;326:42–8. 
[32]  Ton-That H, Mazmanian SK, Faull KF, Schneewind O. Anchoring of surface proteins to the 
cell wall of Staphylococcus aureus. Sortase catalyzed in vitro transpeptidation reaction using 
LPXTG peptide and NH(2)-Gly(3) substrates. J Biol Chem 2000;275:9876–81. 
[33]  Oh K-B, Kim S-H, Lee J, Cho W-J, Lee T, Kim S. Discovery of diarylacrylonitriles as a novel 
series of small molecule sortase A inhibitors. J Med Chem 2004;47:2418–21. 
[34]  Suree N, Yi SW, Thieu W, Marohn M, Damoiseaux R, Chan A, et al. Discovery and 
structure-activity relationship analysis of Staphylococcus aureus sortase A inhibitors. Bioorg 
Med Chem 2009;17:7174–85. 
[35]  Maresso AW, Wu R, Kern JW, Zhang R, Janik D, Missiakas DM, et al. Activation of 
inhibitors by sortase triggers irreversible modification of the active site. J Biol Chem 
2007;282:23129–39. 
[36]  Zong Y, Bice TW, Ton-That H, Schneewind O, Narayana SVL. Crystal structures of 
Staphylococcus aureus sortase A and its substrate complex. J Biol Chem 2004;279:31383–9. 
[37]  Chenna BC, Shinkre BA, King JR, Lucius AL, Narayana SVL, Velu SE. Identification of 
novel inhibitors of bacterial surface enzyme Staphylococcus aureus Sortase A. Bioorg Med 
Chem Lett 2008;18:380–5. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 15
[38]  Chan AH, Wereszczynski J, Amer BR, Yi SW, Jung ME, McCammon JA, et al. Discovery of 
Staphylococcus aureus Sortase A Inhibitors Using Virtual Screening and the Relaxed Complex 
Scheme. Chem Biol Drug Des 2013;82:418–28. 
[39]  Kahlon AK, Negi AS, Kumari R, Srivastava KK, Kumar S, Darokar MP, et al. Identification 
of 1-chloro-2-formyl indenes and tetralenes as novel antistaphylococcal agents exhibiting 
sortase A inhibition. Appl Microbiol Biotechnol 2013. 
[40]  Tian B-X, Eriksson LA. Catalytic mechanism and roles of Arg197 and Thr183 in the 
Staphylococcus aureus sortase A enzyme. J Phys Chem B 2011;115:13003–11. 
[41]  Oh K-B, Nam K-W, Ahn H, Shin J, Kim S, Mar W. Therapeutic effect of (Z)-3-(2,5-
dimethoxyphenyl)-2-(4-methoxyphenyl) acrylonitrile (DMMA) against Staphylococcus aureus 
infection in a murine model. Biochem Biophys Res Commun 2010;396:440–4. 
[42]  Brömme D, Klaus JL, Okamoto K, Rasnick D, Palmer JT. Peptidyl vinyl sulphones: a new 
class of potent and selective cysteine protease inhibitors: S2P2 specificity of human cathepsin 
O2 in comparison with cathepsins S and L. Biochem J 1996;315 ( Pt 1):85–9. 
[43]  Somoza JR, Palmer JT, Ho JD. The crystal structure of human cathepsin F and its 
implications for the development of novel immunomodulators. J Mol Biol 2002;322:559–68. 
[44]  Kudryavtsev KV, Bentley ML, McCafferty DG. Probing of the cis-5-phenyl proline scaffold 
as a platform for the synthesis of mechanism-based inhibitors of the Staphylococcus aureus 
sortase SrtA isoform. Bioorg Med Chem 2009;17:2886–93. 
[45]  Uddin R, Lodhi MU, Ul-Haq Z. Combined pharmacophore and 3D-QSAR study on a series of 
Staphylococcus aureus Sortase A inhibitors. Chem Biol Drug Des 2012;80:300–14. 
[46]  López de Heredia M, Cristóbal S, Hernández ML, Martínez MJ, Ochoa B. The integrity of 
thiol groups is essential for catalytic efficiency of rat liver cholesterol ester hydrolase either in 
microsomal membranes or after solubilization. Enzyme Protein 1996;49:281–90. 
[47]  Sparla F, Preger V, Pupillo P, Trost P. Characterization of a novel NADH-specific, FAD-
containing, soluble reductase with ferric citrate reductase activity from maize seedlings. Arch 
Biochem Biophys 1999;363:301–8. 
[48]  Barnett TC, Scott JR. Differential recognition of surface proteins in Streptococcus pyogenes 
by two sortase gene homologs. J Bacteriol 2002;184:2181–91. 
[49]  Lee Y-J, Han Y-R, Park W, Nam S-H, Oh K-B, Lee H-S. Synthetic analogs of indole-
containing natural products as inhibitors of sortase A and isocitrate lyase. Bioorg Med Chem 
Lett 2010;20:6882–5. 
[50]  Chenna BC, King JR, Shinkre BA, Glover AL, Lucius AL, Velu SE. Synthesis and structure 
activity relationship studies of novel Staphylococcus aureus Sortase A inhibitors. Eur J Med 
Chem 2010;45:3752–61. 
[51]  Kim S-W, Chang I-M, Oh K-B. Inhibition of the bacterial surface protein anchoring 
transpeptidase sortase by medicinal plants. Biosci Biotechnol Biochem 2002;66:2751–4. 
[52]  Kim S-H, Shin D-S, Oh M-N, Chung S-C, Lee J-S, Chang I-M, et al. Inhibition of sortase, a 
bacterial surface protein anchoring transpeptidase, by beta-sitosterol-3-O-glucopyranoside 
from Fritillaria verticillata. Biosci Biotechnol Biochem 2003;67:2477–9. 
[53]  Kang SS, Kim J-G, Lee T-H, Oh K-B. Flavonols inhibit sortases and sortase-mediated 
Staphylococcus aureus clumping to fibrinogen. Biol Pharm Bull 2006;29:1751–5. 
[54]  Huang P, Hu P, Zhou SY, Li Q, Chen WM. Morin Inhibits Sortase A and Subsequent Biofilm 
Formation in Streptococcus mutans. Curr Microbiol 2013. 
[55]  Park B-S, Kim J-G, Kim M-R, Lee S-E, Takeoka GR, Oh K-B, et al. Curcuma longa L. 
constituents inhibit sortase A and Staphylococcus aureus cell adhesion to fibronectin. J Agric 
Food Chem 2005;53:9005–9. 
[56]  Hu P, Huang P, Chen WM. Curcumin Inhibits the Sortase A Activity of the Streptococcus 
mutans UA159. Appl Biochem Biotechnol 2013;171:396–402. 
[57]  Hu P, Huang P, Chen MW. Curcumin reduces Streptococcus mutans biofilm formation by 
inhibiting sortase A activity. Arch Oral Biol 2013;58:1343–8. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 16
[58]  Jenkinson HF, Demuth DR. Structure, function and immunogenicity of streptococcal antigen 
I/II polypeptides. Mol Microbiol 1997;23:183–90. 
[59]  Kim S-H, Shin D-S, Oh M-N, Chung S-C, Lee J-S, Oh K-B. Inhibition of the bacterial surface 
protein anchoring transpeptidase sortase by isoquinoline alkaloids. Biosci Biotechnol Biochem 
2004;68:421–4. 
[60]  Oh I, Yang W-Y, Chung S-C, Kim T-Y, Oh K-B, Shin J. In vitro sortase A inhibitory and 
antimicrobial activity of flavonoids isolated from the roots of Sophora flavescens. Arch Pharm 
Res 2011;34:217–22. 
[61]  Oh K-B, Mar W, Kim S, Kim J-Y, Oh M-N, Kim J-G, et al. Bis(indole) alkaloids as sortase A 
inhibitors from the sponge Spongosorites sp. Bioorg Med Chem Lett 2005;15:4927–31. 
[62]  Jang KH, Chung S-C, Shin J, Lee S-H, Kim T-I, Lee H-S, et al. Aaptamines as sortase A 
inhibitors from the tropical sponge Aaptos aaptos. Bioorg Med Chem Lett 2007;17:5366–9. 
[63]  Jeon J-E, Na Z, Jung M, Lee H-S, Sim CJ, Nahm K, et al. Discorhabdins from the Korean 
marine sponge Sceptrella sp. J Nat Prod 2010;73:258–62. 
[64]  Bae J, Jeon J-E, Lee Y-J, Lee H-S, Sim CJ, Oh K-B, et al. Sesterterpenes from the tropical 
sponge Coscinoderma sp. J Nat Prod 2011;74:1805–11. 
[65]  Won TH, Jeon J, Kim S-H, Lee S-H, Rho BJ, Oh D-C, et al. Brominated aromatic furanones 
and related esters from the ascidian Synoicum sp. J Nat Prod 2012;75:2055–61. 
[66]  Won TH, Jeon J-E, Lee S-H, Rho BJ, Oh K-B, Shin J. Beta-carboline alkaloids derived from 
the ascidian Synoicum sp. Bioorg Med Chem 2012;20:4082–7. 
[67]  Scott CJ, McDowell A, Martin SL, Lynas JF, Vandenbroeck K, Walker B. Irreversible 
inhibition of the bacterial cysteine protease-transpeptidase sortase (SrtA) by substrate-derived 
affinity labels. Biochem J 2002;366:953–8. 
[68]  Connolly KM, Smith BT, Pilpa R, Ilangovan U, Jung ME, Clubb RT. Sortase from 
Staphylococcus aureus does not contain a thiolate-imidazolium ion pair in its active site. J Biol 
Chem 2003;278:34061–5. 
[69]  Jung ME, Clemens JJ, Suree N, Liew CK, Pilpa R, Campbell DO, et al. Synthesis of (2R,3S) 
3-amino-4-mercapto-2-butanol, a threonine analogue for covalent inhibition of sortases. 
Bioorg Med Chem Lett 2005;15:5076–9. 
[70]  Kruger RG, Barkallah S, Frankel BA, McCafferty DG. Inhibition of the Staphylococcus 
aureus sortase transpeptidase SrtA by phosphinic peptidomimetics. Bioorg Med Chem 
2004;12:3723–9. 
[71]  Copié V, Kolbert AC, Drewry DH, Bartlett PA, Oas TG, Griffin RG. Inhibition of 
thermolysin by phosphonamidate transition-state analogues: measurement of 31P-15N bond 
lengths and chemical shifts in two enzyme-inhibitor complexes by solid-state nuclear magnetic 
resonance. Biochemistry (Mosc) 1990;29:9176–84. 
[72]  Yiallouros I, Vassiliou S, Yiotakis A, Zwilling R, Stöcker W, Dive V. Phosphinic peptides, 
the first potent inhibitors of astacin, behave as extremely slow-binding inhibitors. Biochem J 
1998;331 ( Pt 2):375–9. 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
Table 2 Activity of the most representative SrtA inhibitors belonging to natural compounds 
 
Name Source SrtA IC50 (µg/ml) Fibronectin binding 
inhibition 
µg/ml 
MIC (µg/ml) References 
β-sitosterol-3-O-
glucopyranoside 
F.verticillata 18.3 (S. aureus) N.D. 200 (S. aureus) 52 
Morin Chinese herbs and 
fruit 
11.29 (S. aureus) 
8.21 (S. mutans) 
Dose dependent > 900 (S. aureus) 53, 54 
Myricetin Chinese herbs and 
fruit 
13.99 (S. aureus) Dose dependent > 900 (S. aureus) 53 
Quercetin Rhus verniciflua 15.91 (S. aureus) Dose dependent > 900 (S. aureus) 53 
Curcumin C. longa L. 13.8 (S. aureus) 
3.6 (S. mutans) 
Dose dependent  2.5-20 
N.D. 
>200 (S. aureus) 
61.7 (S. mutans) 
55 
56, 57 
Berberine chloride C. chinensis 8.7 (S. aureus) N.D. 100 (S. aureus) 59 
Kurarinol S. flavescens 48.8 (S. aureus) N.D. 99 (S. aureus) 60 
Deoxytopsentin Spongosorites sp 15.6 (S. aureus) N.D. 6.25 (S. aureus) 61 
Bromodeoxytopsentin Spongosorites sp 19.4 (S. aureus) Dose dependent 0-40 100 (S. aureus) 61 
Isoaaptamin A. aaptos 3.7 (S. aureus) Dose dependent 0-16 50 (S. aureus) 62 
(-)-discorhabdin Z Sceptrella sp. 2.19 (S. aureus) N.D. >100 (S. aureus)  63 
Halisulfate 1 Coscinoderma sp. 21.34 (S. aureus) N.D. 1.56-25 (S. aureus) 64 
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Table 1. Examples of LPXTG proteins from S.aureus 
 
Name Abb. Function Pathogenic process Protein function 
signal 
Collagen–binding 
adhesin 
Cna 
 
Adhesin for collagen (type I 
and IV) 
Adhesion LPKTG 
Clumping factor A ClfA Platelet adhesion (fibrin-
mediated); binds 
complement regulator factor 
I 
Adhesion; colonization; evasion 
of innate immune defenses 
LPDTG 
 
Clumping factor  B ClfB 
 
Platelet adhesion (fibrin-
mediated); binds cytokeratin 
10 
Adhesion; colonization; evasion 
of innate immune defenses 
LPETG 
Fibronectin-binding 
protein homolog 
FnbA 
 
Adhesin for fibrinogen, 
fibronectin and elaststin 
Adhesion; colonization;  biofilm 
formation 
LPETG 
Fibronectin-binding 
protein homolog 
FnbB 
 
Adhesin for fibronectin and 
elastin 
Adhesion; colonization; biofilm 
formation 
LPETG 
Serin-Aspartate 
repeat protein C 
SdrC 
 
 
Adhesin Adhesion; colonization LPETG 
Serin-Aspartate 
repeat protein D 
SdrD Adhesin Adhesion; colonization LPETG 
Serin-Aspartate 
repeat protein E 
SdrE Adhesin Adhesion; colonization LPETG 
Protein A Spa 
 
Binds Fc domain for 
immunoglobulins; binds 
complement protein C3 
Interference with innate and 
adaptive immune responses 
LPETG 
S.aureus surface 
protein C 
SasC 
 
Binds extracellular matrix Adhesion; biofilm formation LPNTG 
S.aureus surface 
protein G 
SasG 
 
Binds extracellular matrix Adhesion; biofilm formation LPDTG 
Iron-regulated 
surface determinant 
A 
IsdA 
 
Adhesion factor for 
fibronectin, fibrinogen, 
transferrin, haemoglobin 
(expressed in iron-restricted 
environment) 
Adhesion; colonization LPKTG 
Plasmin sensitive 
protein 
Pls Methicillin resistant surface 
protein 
Resistance LPDTG 
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Highlights 
• Antibiotic-resistance of Gram-positive pathogens is a major worldwide health 
problem  
• It is necessary to develop alternative strategies to conventional antibiotics in 
the struggle against harmful Gram-positive pathogens  
• Anti-virulence drugs target the virulence of pathogens without killing or 
inhibiting the growth of microorganisms.  
• Anti-virulence drugs have a limited selective pressure to promote the rise in 
antibiotic-resistance strains.  
• The Sortase A (SrtA) is a transpeptidase responsible for the anchoring of 
MSCRAMMs (microbial surface components recognizing adhesive matrix 
molecules) proteins to the cell wall of many Gram-positive pathogens 
• MSCRAMMs are involved in many mechanisms of virulence as adhesion, 
invasion, colonization, immune evasion and biofilm formation  
• The SrtA is an attractive target to design new anti-virulence agents 
• Many inhibitors of SrtA, small synthetic compounds or natural products, have 
been identified. Some of them are potential leading compounds in the 
development of anti-virulence agents 
• One of the gaps of knowledge in this research field is the lack of assessment of 
the efficacy of most SrtA inhibitors by using in vitro or in vivo models of 
infections 
• Further studies to improve the pharmaceutical potential of anti-sortase agents 
are needed  
• The possibility of using novel anti-virulence agents in combination with 
current antibiotics is a potential new therapeutic strategy in the treatment of 
infectious disease and can contribute to overcoming antibiotic-resistance. 
 
 
